Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1981 Nov;12(5):743–747. doi: 10.1111/j.1365-2125.1981.tb01299.x

Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency.

G T McInnes, I R Harrison, J R Shelton, R M Perkins
PMCID: PMC1401948  PMID: 7332740

Abstract

1 The potency of single doses of the aldosterone antagonist SC8109 relative to spironolactone in reversing the urinary electrolyte effects of fludrocortisone was examined in a double-blind, balanced, crossover study in six healthy volunteers. 2 For the urinary ratio log10 10Na/K, the relative potency of SC8109; spironolactone on a weight basis was 0.08:1 (95% confidence limits 0.04--0.13:1). 3 The potency of SC8109 relative to spironolactone for natriuresis and antikaliuresis was 0.10:1 and 0.05:1, respectively. 4 The results show excellent agreement with clinical experience where SC8109 was considered to have one tenth the potency of spironolactone. We suggest that the human bioassay employed in this study provides quantitative information which should be predictive of the therapeutic potency of aldosterone antagonists.

Full text

PDF
743

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BOLTE E., VERDY M., MARC-AURELE J., BROUILLET J., BEAUREGARD P., GENEST J. Studies on new diuretic compounds: spirolactone and chlorothiazide. Can Med Assoc J. 1958 Dec 1;79(11):881–888. [PMC free article] [PubMed] [Google Scholar]
  2. DRILL V. A. The aldosterone blocking effects of spirolactones. Jpn J Pharmacol. 1962 Mar;11:77–87. doi: 10.1254/jjp.11.77. [DOI] [PubMed] [Google Scholar]
  3. GANTT C. L. Aldosterone antagonists. N Y State J Med. 1961 Mar 1;61:756–770. [PubMed] [Google Scholar]
  4. GANTT C. L., DYNIEWICZ J. M. QUANTITATION OF MINERALOCORTICOID ACTIVITY AND ANTAGONISM IN NORMAL SUBJECTS. Metabolism. 1963 Nov;12:1007–1011. [PubMed] [Google Scholar]
  5. HELLMAN S., FALOON W. W. The sodium excretion defect in hepatic cirrhosis as studied by the use of a steroidal lactone. J Lab Clin Med. 1960 Jun;55:872–882. [PubMed] [Google Scholar]
  6. JOHNSON B. B. Bioassay of adrenal cortical steroids on the basis of electrolyte excretion by rats: effects of 11-desoxy and 11-oxy-steroids. Endocrinology. 1954 Feb;54(2):196–208. doi: 10.1210/endo-54-2-196. [DOI] [PubMed] [Google Scholar]
  7. KAGAWA C. M. Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone. Endocrinology. 1960 Jul;67:125–132. doi: 10.1210/endo-67-1-125. [DOI] [PubMed] [Google Scholar]
  8. KAGAWA C. M., CELLA J. A., VAN ARMAN C. G. Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science. 1957 Nov 15;126(3281):1015–1016. doi: 10.1126/science.126.3281.1015. [DOI] [PubMed] [Google Scholar]
  9. KAGAWA C. M., STURTEVANT F. M., VAN ARMAN C. G. Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone. J Pharmacol Exp Ther. 1959 Jun;126(2):123–130. [PubMed] [Google Scholar]
  10. KERR D. N., READ A. E., HASLAM R. M., SHERLOCK S. The use of a steroidal spirolactone in the treatment of ascites in hepatic cirrhosis. Lancet. 1958 Nov 22;2(7056):1084–1087. doi: 10.1016/s0140-6736(58)92464-4. [DOI] [PubMed] [Google Scholar]
  11. LIDDLE G. W. Aldosterone antagonists. AMA Arch Intern Med. 1958 Dec;102(6):998–1004. doi: 10.1001/archinte.1958.00260230144018. [DOI] [PubMed] [Google Scholar]
  12. LIDDLE G. W. Sodium diuresis induced by steroidal antagonists of aldosterone. Science. 1957 Nov 15;126(3281):1016–1018. doi: 10.1126/science.126.3281.1016. [DOI] [PubMed] [Google Scholar]
  13. Ochs H. R., Greenblatt D. J., Bodem G., Smith T. W. Spironolactone. Am Heart J. 1978 Sep;96(3):389–400. doi: 10.1016/0002-8703(78)90052-2. [DOI] [PubMed] [Google Scholar]
  14. PLAYOUST M. R., BLACKBURN C. R. The use of an aldosterone antagonist in patients with cirrhosis. Australas Ann Med. 1960 Feb;9:64–68. doi: 10.1111/imj.1960.9.1.64. [DOI] [PubMed] [Google Scholar]
  15. ROSS E. J., BETHUNE J. E. Antagonism between the effect of aldosterone and a synthetic steroid lactone on the renal excretion of sodium and potassium in man. Lancet. 1959 Jan 17;1(7064):127–129. doi: 10.1016/s0140-6736(59)90006-6. [DOI] [PubMed] [Google Scholar]
  16. ROSS E. J. Human assay of electrolyte-active steroids and their antagonists. Clin Sci. 1962 Oct;23:197–202. [PubMed] [Google Scholar]
  17. Ramsay L. E., Hessian P., Tidd M. J. Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses. Br J Clin Pharmacol. 1975 Jun;2(3):271–276. doi: 10.1111/j.1365-2125.1975.tb01587.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ramsay L., Harrison I., Shelton J., Tidd M. Relative potency of prorenoate and spironolactone in normal man. Clin Pharmacol Ther. 1975 Oct;18(4):391–400. doi: 10.1002/cpt1975184391. [DOI] [PubMed] [Google Scholar]
  19. Ramsay L., Shelton J., Harrison I., Tidd M., Asbury M. Spironolactone and potassium canrenoate in normal man. Clin Pharmacol Ther. 1976 Aug;20(2):167–177. doi: 10.1002/cpt1976202167. [DOI] [PubMed] [Google Scholar]
  20. SALASSA R. M., MATTOX V. R., POWER M. H. Effect of an aldosterone antagonist on sodium and potassium excretion in primary hyperaldosteronism. J Clin Endocrinol Metab. 1958 Jul;18(7):787–789. doi: 10.1210/jcem-18-7-787. [DOI] [PubMed] [Google Scholar]
  21. SHALDON S., RYDER J. A., GARSENSTEIN M. A comparison of the use of Aldactone and Aldactone A in the treatment of hepatic ascites. Gut. 1963 Mar;4:16–19. doi: 10.1136/gut.4.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. SLATER J. D. Aldosterone antagonism by 17-spirolactosteroids. Postgrad Med J. 1960 Jun;36:399–405. doi: 10.1136/pgmj.36.416.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. SLATER J. D., MOXHAM A., HURTER R., NABARRO J. D. Clinical and metabolic effects of aldosterone antagonism. Lancet. 1959 Nov 28;2(7109):931–934. doi: 10.1016/s0140-6736(59)91584-3. [DOI] [PubMed] [Google Scholar]
  24. Tweeddale M. G., Ogilvie R. I. Antagonism of spironolactone-induced natriuresis by aspirin in man. N Engl J Med. 1973 Jul 26;289(4):198–200. doi: 10.1056/NEJM197307262890408. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES